Drug Patents owned by Sucampo Pharma Llc

1. Drug name - AMITIZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8097653 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation Nov, 2022

(a month from now)

US8389542 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation Nov, 2022

(a month from now)

US6982283 SUCAMPO PHARMA LLC Method for treating drug-induced constipation Dec, 2022

(2 months from now)

US7795312 SUCAMPO PHARMA LLC Method for treating abdominal discomfort Sep, 2024

(1 year, 11 months from now)

US8748481 SUCAMPO PHARMA LLC Method for treating gastrointestinal disorder Sep, 2025

(2 years from now)

US8779187 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation Jan, 2027

(4 years from now)

US8338639 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation Jan, 2027

(4 years from now)

US8026393 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation Oct, 2027

(5 years from now)

Drugs and Companies using LUBIPROSTONE ingredient

Treatment: Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient; Method for treating opioid-induced constipation; Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome; Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; method for the long term treatment of chronic constipation in a human subject

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
8MCG CAPSULE;ORAL Prescription
24MCG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.